^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CAM-H2

    i
    Other names: CAM-H2, 131-Iodine conjugated anti-HER2 sdAb 2Rs15d, Iodine-131-SGMIB anti-HER2 VHH1, CAM-H2-I-131
    Associations

    News

    Trials
    Company:
    Precirix
    Drug class:
    HER2 inhibitor, Beta radiation emitter
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P1/2, N=13, Terminated, Precirix | Active, not recruiting --> Terminated; Per Strategic Sponsor decision
    Trial termination • Metastases
    |
    HER-2 positive
    |
    CAM-H2
    almost2years
    A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, Precirix | Recruiting --> Active, not recruiting | N=70 --> 13 | Trial completion date: Jan 2025 --> Jan 2024 | Trial primary completion date: Jan 2025 --> Dec 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 positive
    |
    CAM-H2